{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:47:11Z","timestamp":1790437631621,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40291-021-00558-y","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:15:52Z","timestamp":1634606152000},"page":"661-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-8807","authenticated-orcid":false,"given":"Vasiliki","family":"Kalatzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Fran\u00e7oise","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/bs.pmbts.2015.06.001","volume":"134","author":"HE Grossniklaus","year":"2015","unstructured":"Grossniklaus HE, Geisert EE, Nickerson JM. Introduction to the retina. Prog Mol Biol Transl Sci. 2015;134:383\u201396. https:\/\/doi.org\/10.1016\/bs.pmbts.2015.06.001.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"558_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.2174\/156652410793937813","volume":"10","author":"JR Sparrow","year":"2010","unstructured":"Sparrow JR, Hicks D, Hamel CP. The retinal pigment epithelium in health and disease. Curr Mol Med. 2010;10:802\u201323.","journal-title":"Curr Mol Med"},{"key":"558_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","volume":"85","author":"O Strauss","year":"2005","unstructured":"Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845\u201381. https:\/\/doi.org\/10.1152\/physrev.00021.2004.","journal-title":"Physiol Rev"},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/bs.pmbts.2015.06.014","volume":"134","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Wildsoet CF. RPE and choroid mechanisms underlying ocular growth and myopia. Prog Mol Biol Transl Sci. 2015;134:221\u201340. https:\/\/doi.org\/10.1016\/bs.pmbts.2015.06.014.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"558_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100803","author":"MA Fields","year":"2019","unstructured":"Fields MA, Del Priore LV, Adelman RA, Rizzolo LJ. Interactions of the choroid, Bruch\u2019s membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood\u2013retinal-barrier. Prog Retin Eye Res. 2019. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.100803.","journal-title":"Prog Retin Eye Res"},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s1357-4310(96)10037-x","volume":"2","author":"LS Sullivan","year":"1996","unstructured":"Sullivan LS, Daiger SP. Inherited retinal degeneration: exceptional genetic and clinical heterogeneity. Mol Med Today. 1996;2:380\u20136. https:\/\/doi.org\/10.1016\/s1357-4310(96)10037-x.","journal-title":"Mol Med Today"},{"key":"558_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","volume":"66","author":"SK Verbakel","year":"2018","unstructured":"Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157\u201386. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.03.005.","journal-title":"Prog Retin Eye Res"},{"key":"558_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","volume":"29","author":"W Berger","year":"2010","unstructured":"Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29:335\u201375. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.03.004.","journal-title":"Prog Retin Eye Res"},{"key":"558_CR9","doi-asserted-by":"publisher","first-page":"433 e3","DOI":"10.1016\/j.ajo.2013.05.009","volume":"156","author":"V Kalatzis","year":"2013","unstructured":"Kalatzis V, Hamel CP, MacDonald IM. Symposium obotFICR. Choroideremia: towards a therapy. Am J Ophthalmol. 2013;156:433 e3-437 e3. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.009.","journal-title":"Am J Ophthalmol"},{"key":"558_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mgg3.208","volume":"4","author":"PR Freund","year":"2016","unstructured":"Freund PR, Sergeev YV, MacDonald IM. Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy. Mol Genet Genomic Med. 2016;4:344\u201358. https:\/\/doi.org\/10.1002\/mgg3.208.","journal-title":"Mol Genet Genomic Med"},{"key":"558_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/bjo.86.6.658","volume":"86","author":"MF Roberts","year":"2002","unstructured":"Roberts MF, Fishman GA, Roberts DK, Heckenlively JR, Weleber RG, Anderson RJ, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol. 2002;86:658\u201362. https:\/\/doi.org\/10.1136\/bjo.86.6.658.","journal-title":"Br J Ophthalmol"},{"key":"558_CR12","volume-title":"Molecular genetics of choroideremia. eLS","author":"PR Freund","year":"2012","unstructured":"Freund PR, MacDonald IM. Molecular genetics of choroideremia. eLS. Chichester: Wiley; 2012."},{"key":"558_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archopht.125.8.1107","volume":"125","author":"M Mura","year":"2007","unstructured":"Mura M, Sereda C, Jablonski MM, MacDonald IM, Iannaccone A. Clinical and functional findings in choroideremia due to complete deletion of the CHM gene. Arch Ophthalmol. 2007;125:1107\u201313. https:\/\/doi.org\/10.1001\/archopht.125.8.1107.","journal-title":"Arch Ophthalmol"},{"key":"558_CR14","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.ophtha.2016.02.025","volume":"123","author":"N Nabholz","year":"2016","unstructured":"Nabholz N, Lorenzini MC, Bocquet B, Lacroux A, Faugere V, Roux AF, et al. Clinical evaluation and cone alterations in choroideremia. Ophthalmology. 2016;123:1830\u20132. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.025.","journal-title":"Ophthalmology"},{"key":"558_CR15","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1167\/iovs.06-0424","volume":"47","author":"SG Jacobson","year":"2006","unstructured":"Jacobson SG, Cideciyan AV, Sumaroka A, Aleman TS, Schwartz SB, Windsor EA, et al. Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. Invest Ophthalmol Vis Sci. 2006;47:4113\u201320. https:\/\/doi.org\/10.1167\/iovs.06-0424.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"558_CR16","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.ophtha.2004.04.028","volume":"111","author":"MJ Potter","year":"2004","unstructured":"Potter MJ, Wong E, Szabo SM, McTaggart KE. Clinical findings in a carrier of a new mutation in the choroideremia gene. Ophthalmology. 2004;111:1905\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2004.04.028.","journal-title":"Ophthalmology"},{"key":"558_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/347674a0","volume":"347","author":"FP Cremers","year":"1990","unstructured":"Cremers FP, van de Pol DJ, van Kerkhoff LP, Wieringa B, Ropers HH. Cloning of a gene that is rearranged in patients with choroideraemia. Nature. 1990;347:674\u20137. https:\/\/doi.org\/10.1038\/347674a0.","journal-title":"Nature"},{"key":"558_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/hmg\/3.7.1041","volume":"3","author":"H van Bokhoven","year":"1994","unstructured":"van Bokhoven H, van den Hurk JA, Bogerd L, Philippe C, Gilgenkrantz S, de Jong P, et al. Cloning and characterization of the human choroideremia gene. Hum Mol Genet. 1994;3:1041\u20136.","journal-title":"Hum Mol Genet"},{"key":"558_CR19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","volume":"124","author":"EM Stone","year":"2017","unstructured":"Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124:1314\u201331. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.008.","journal-title":"Ophthalmology"},{"key":"558_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/humu.23212","volume":"38","author":"A Radziwon","year":"2017","unstructured":"Radziwon A, Arno G, Wheaton DK, McDonagh EM, Baple EL, Webb-Jones K, et al. Single-base substitutions in the CHM promoter as a cause of choroideremia. Hum Mutat. 2017;38:704\u201315. https:\/\/doi.org\/10.1002\/humu.23212.","journal-title":"Hum Mutat"},{"key":"558_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/humu.23671","volume":"40","author":"C Vache","year":"2019","unstructured":"Vache C, Torriano S, Faugere V, Erkilic N, Baux D, Garcia-Garcia G, et al. Pathogenicity of novel atypical variants leading to choroideremia as determined by functional analyses. Hum Mutat. 2019;40:31\u20135. https:\/\/doi.org\/10.1002\/humu.23671.","journal-title":"Hum Mutat"},{"key":"558_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00439-003-0970-0","volume":"113","author":"JA van den Hurk","year":"2003","unstructured":"van den Hurk JA, van de Pol DJ, Wissinger B, van Driel MA, Hoefsloot LH, de Wijs IJ, et al. Novel types of mutation in the choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon. Hum Genet. 2003;113:268\u201375. https:\/\/doi.org\/10.1007\/s00439-003-0970-0.","journal-title":"Hum Genet"},{"key":"558_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ajhg.2016.12.003","volume":"100","author":"KJ Carss","year":"2017","unstructured":"Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. Am J Hum Genet. 2017;100:75\u201390. https:\/\/doi.org\/10.1016\/j.ajhg.2016.12.003.","journal-title":"Am J Hum Genet"},{"key":"558_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/humu.24174","volume":"42","author":"C Zeitz","year":"2021","unstructured":"Zeitz C, Nassisi M, Laurent-Coriat C, Andrieu C, Boyard F, Condroyer C, et al. CHM mutation spectrum and disease: an update at the time of human therapeutic trials. Hum Mutat. 2021;42:323\u201341. https:\/\/doi.org\/10.1002\/humu.24174.","journal-title":"Hum Mutat"},{"key":"558_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/ICU.0000000000000392","volume":"28","author":"IS Dimopoulos","year":"2017","unstructured":"Dimopoulos IS, Radziwon A, St Laurent CD, MacDonald IM. Choroideremia. Curr Opin Ophthalmol. 2017;28:410\u20135. https:\/\/doi.org\/10.1097\/ICU.0000000000000392.","journal-title":"Curr Opin Ophthalmol"},{"key":"558_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mrfmmm.2009.02.015","volume":"665","author":"YV Sergeev","year":"2009","unstructured":"Sergeev YV, Smaoui N, Sui R, Stiles D, Gordiyenko N, Strunnikova N, et al. The functional effect of pathogenic mutations in Rab escort protein 1. Mutat Res. 2009;665:44\u201350. https:\/\/doi.org\/10.1016\/j.mrfmmm.2009.02.015.","journal-title":"Mutat Res"},{"key":"558_CR27","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/humu.21591","volume":"32","author":"G Esposito","year":"2011","unstructured":"Esposito G, De Falco F, Tinto N, Testa F, Vitagliano L, Tandurella IC, et al. Comprehensive mutation analysis (20 families) of the choroideremia gene reveals a missense variant that prevents the binding of REP1 with Rab geranylgeranyl transferase. Hum Mutat. 2011;32:1460\u20139. https:\/\/doi.org\/10.1002\/humu.21591.","journal-title":"Hum Mutat"},{"key":"558_CR28","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1093\/hmg\/ddx244","volume":"26","author":"S Torriano","year":"2017","unstructured":"Torriano S, Erkilic N, Faugere V, Damodar K, Hamel CP, Roux AF, et al. Pathogenicity of a novel missense variant associated with choroideremia and its impact on gene replacement therapy. Hum Mol Genet. 2017;26:3573\u201384. https:\/\/doi.org\/10.1093\/hmg\/ddx244.","journal-title":"Hum Mol Genet"},{"key":"558_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151943","volume":"11","author":"R Sanchez-Alcudia","year":"2016","unstructured":"Sanchez-Alcudia R, Garcia-Hoyos M, Lopez-Martinez MA, Sanchez-Bolivar N, Zurita O, Gimenez A, et al. A Comprehensive analysis of choroideremia: from genetic characterization to clinical practice. PLoS ONE. 2016;11: e0151943. https:\/\/doi.org\/10.1371\/journal.pone.0151943.","journal-title":"PLoS ONE"},{"key":"558_CR30","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1167\/iovs.16-20230","volume":"57","author":"MP Simunovic","year":"2016","unstructured":"Simunovic MP, Jolly JK, Xue K, Edwards TL, Groppe M, Downes SM, et al. The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype. Invest Ophthalmol Vis Sci. 2016;57:6033\u20139. https:\/\/doi.org\/10.1167\/iovs.16-20230.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"558_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2019.5071","volume":"139","author":"LE Fry","year":"2019","unstructured":"Fry LE, Patricio MI, Williams J, Aylward JW, Hewitt H, Clouston P, et al. Association of messenger RNA level with phenotype in patients with choroideremia: potential implications for gene therapy dose. JAMA Ophthalmol. 2019;139:319\u201328. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5071.","journal-title":"JAMA Ophthalmol."},{"key":"558_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1152\/physrev.00059.2009","volume":"91","author":"AH Hutagalung","year":"2011","unstructured":"Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91:119\u201349. https:\/\/doi.org\/10.1152\/physrev.00059.2009.","journal-title":"Physiol Rev"},{"key":"558_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1471-4914(01)02227-4","volume":"8","author":"MC Seabra","year":"2002","unstructured":"Seabra MC, Mules EH, Hume AN. Rab GTPases, intracellular traffic and disease. Trends Mol Med. 2002;8:23\u201330.","journal-title":"Trends Mol Med"},{"key":"558_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0014-5793(01)02483-8","volume":"498","author":"JB Pereira-Leal","year":"2001","unstructured":"Pereira-Leal JB, Hume AN, Seabra MC. Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett. 2001;498:197\u2013200. https:\/\/doi.org\/10.1016\/s0014-5793(01)02483-8.","journal-title":"FEBS Lett"},{"key":"558_CR35","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1002\/j.1460-2075.1994.tb06860.x","volume":"13","author":"K Alexandrov","year":"1994","unstructured":"Alexandrov K, Horiuchi H, Steele-Mortimer O, Seabra MC, Zerial M. Rab escort protein-1 is a multifunctional protein that accompanies newly prenylated rab proteins to their target membranes. EMBO J. 1994;13:5262\u201373.","journal-title":"EMBO J"},{"key":"558_CR36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1034\/j.1600-0854.2001.20803.x","volume":"2","author":"C Alory","year":"2001","unstructured":"Alory C, Balch WE. Organization of the Rab-GDI\/CHM superfamily: the functional basis for choroideremia disease. Traffic. 2001;2:532\u201343.","journal-title":"Traffic"},{"key":"558_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0092-8674(93)90639-8","volume":"73","author":"DA Andres","year":"1993","unstructured":"Andres DA, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FP, et al. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell. 1993;73:1091\u20139.","journal-title":"Cell"},{"key":"558_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1126\/science.8380507","volume":"259","author":"MC Seabra","year":"1993","unstructured":"Seabra MC, Brown MS, Goldstein JL. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science. 1993;259:377\u201381.","journal-title":"Science"},{"key":"558_CR39","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0092-8674(92)90253-9","volume":"70","author":"MC Seabra","year":"1992","unstructured":"Seabra MC, Brown MS, Slaughter CA, Sudhof TC, Goldstein JL. Purification of component A of Rab geranylgeranyl transferase: possible identity with the choroideremia gene product. Cell. 1992;70:1049\u201357.","journal-title":"Cell"},{"key":"558_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/hmg\/1.2.71","volume":"1","author":"FP Cremers","year":"1992","unstructured":"Cremers FP, Molloy CM, van de Pol DJ, van den Hurk JA, Bach I, Geurts van Kessel AH, et al. An autosomal homologue of the choroideremia gene colocalizes with the Usher syndrome type II locus on the distal part of chromosome 1q. Hum Mol Genet. 1992;1:71\u20135.","journal-title":"Hum Mol Genet"},{"key":"558_CR41","doi-asserted-by":"publisher","first-page":"24420","DOI":"10.1074\/jbc.270.41.24420","volume":"270","author":"MC Seabra","year":"1995","unstructured":"Seabra MC, Ho YK, Anant JS. Deficient geranylgeranylation of Ram\/Rab27 in choroideremia. J Biol Chem. 1995;270:24420\u20137.","journal-title":"J Biol Chem"},{"key":"558_CR42","doi-asserted-by":"publisher","first-page":"46798","DOI":"10.1074\/jbc.M307799200","volume":"278","author":"B Larijani","year":"2003","unstructured":"Larijani B, Hume AN, Tarafder AK, Seabra MC. Multiple factors contribute to inefficient prenylation of Rab27a in Rab prenylation diseases. J Biol Chem. 2003;278:46798\u2013804. https:\/\/doi.org\/10.1074\/jbc.M307799200.","journal-title":"J Biol Chem"},{"key":"558_CR43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2004.05.017","volume":"117","author":"A Rak","year":"2004","unstructured":"Rak A, Pylypenko O, Niculae A, Pyatkov K, Goody RS, Alexandrov K. Structure of the Rab7:REP-1 complex: insights into the mechanism of Rab prenylation and choroideremia disease. Cell. 2004;117:749\u201360. https:\/\/doi.org\/10.1016\/j.cell.2004.05.017.","journal-title":"Cell"},{"key":"558_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081758","volume":"8","author":"M Kohnke","year":"2013","unstructured":"Kohnke M, Delon C, Hastie ML, Nguyen UT, Wu YW, Waldmann H, et al. Rab GTPase prenylation hierarchy and its potential role in choroideremia disease. PLoS ONE. 2013;8: e81758. https:\/\/doi.org\/10.1371\/journal.pone.0081758.","journal-title":"PLoS ONE"},{"key":"558_CR45","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1073\/pnas.0308474100","volume":"101","author":"CJ Starr","year":"2004","unstructured":"Starr CJ, Kappler JA, Chan DK, Kollmar R, Hudspeth AJ. Mutation of the zebrafish choroideremia gene encoding Rab escort protein 1 devastates hair cells. Proc Natl Acad Sci USA. 2004;101:2572\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"558_CR46","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1167\/iovs.08-2755","volume":"50","author":"M Moosajee","year":"2009","unstructured":"Moosajee M, Tulloch M, Baron RA, Gregory-Evans CY, Pereira-Leal JB, Seabra MC. Single choroideremia gene in nonmammalian vertebrates explains early embryonic lethality of the zebrafish model of choroideremia. Invest Ophthalmol Vis Sci. 2009;50:3009\u201316. https:\/\/doi.org\/10.1167\/iovs.08-2755.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"558_CR47","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1073\/pnas.0605818104","volume":"104","author":"BL Krock","year":"2007","unstructured":"Krock BL, Bilotta J, Perkins BD. Noncell-autonomous photoreceptor degeneration in a zebrafish model of choroideremia. Proc Natl Acad Sci USA. 2007;104:4600\u20135. https:\/\/doi.org\/10.1073\/pnas.0605818104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"558_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.ctdb.2019.02.004","volume":"134","author":"ME Kossack","year":"2019","unstructured":"Kossack ME, Draper BW. Genetic regulation of sex determination and maintenance in zebrafish (Danio rerio). Curr Top Dev Biol. 2019;134:119\u201349. https:\/\/doi.org\/10.1016\/bs.ctdb.2019.02.004.","journal-title":"Curr Top Dev Biol"},{"key":"558_CR49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/hmg\/6.6.851","volume":"6","author":"JA van den Hurk","year":"1997","unstructured":"van den Hurk JA, Hendriks W, van de Pol DJ, Oerlemans F, Jaissle G, Ruther K, et al. Mouse choroideremia gene mutation causes photoreceptor cell degeneration and is not transmitted through the female germline. Hum Mol Genet. 1997;6:851\u20138.","journal-title":"Hum Mol Genet"},{"key":"558_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ydbio.2004.04.016","volume":"272","author":"W Shi","year":"2004","unstructured":"Shi W, van den Hurk JA, Alamo-Bethencourt V, Mayer W, Winkens HJ, Ropers HH, et al. Choroideremia gene product affects trophoblast development and vascularization in mouse extra-embryonic tissues. Dev Biol. 2004;272:53\u201365. https:\/\/doi.org\/10.1016\/j.ydbio.2004.04.016.","journal-title":"Dev Biol"},{"key":"558_CR51","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI26617","volume":"116","author":"T Tolmachova","year":"2006","unstructured":"Tolmachova T, Anders R, Abrink M, Bugeon L, Dallman MJ, Futter CE, et al. Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia. J Clin Invest. 2006;116:386\u201394.","journal-title":"J Clin Invest"},{"key":"558_CR52","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1167\/iovs.09-4892","volume":"51","author":"T Tolmachova","year":"2010","unstructured":"Tolmachova T, Wavre-Shapton ST, Barnard AR, MacLaren RE, Futter CE, Seabra MC. Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia. Invest Ophthalmol Vis Sci. 2010;51:4913\u201320. https:\/\/doi.org\/10.1167\/iovs.09-4892.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"558_CR53","doi-asserted-by":"publisher","first-page":"5056279","DOI":"10.1155\/2018\/5056279","volume":"2018","author":"C Sanjurjo-Soriano","year":"2018","unstructured":"Sanjurjo-Soriano C, Kalatzis V. Guiding lights in genome editing for inherited retinal disorders: implications for gene and cell therapy. Neural Plast. 2018;2018:5056279. https:\/\/doi.org\/10.1155\/2018\/5056279.","journal-title":"Neural Plast"},{"key":"558_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/21678707.2021.1882300","volume":"9","author":"RC Han","year":"2021","unstructured":"Han RC, Fry LE, Kantor A, McClements ME, Xue K, MacLaren RE. Is subretinal AAV gene replacement still the only viable treatment option for choroideremia? Expert Opin Orphan Drugs. 2021;9:13\u201324. https:\/\/doi.org\/10.1080\/21678707.2021.1882300.","journal-title":"Expert Opin Orphan Drugs"},{"key":"558_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/978-3-319-17121-0_69","volume":"854","author":"X Gerard","year":"2016","unstructured":"Gerard X, Garanto A, Rozet JM, Collin RW. Antisense oligonucleotide therapy for inherited retinal dystrophies. Adv Exp Med Biol. 2016;854:517\u201324. https:\/\/doi.org\/10.1007\/978-3-319-17121-0_69.","journal-title":"Adv Exp Med Biol"},{"key":"558_CR56","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1086\/507318","volume":"79","author":"AI den Hollander","year":"2006","unstructured":"den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet. 2006;79:556\u201361. https:\/\/doi.org\/10.1086\/507318.","journal-title":"Am J Hum Genet"},{"key":"558_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.3","volume":"1","author":"RW Collin","year":"2012","unstructured":"Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, Cremers FP. Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290. Mol Ther Nucleic Acids. 2012;1: e14. https:\/\/doi.org\/10.1038\/mtna.2012.3.","journal-title":"Mol Ther Nucleic Acids."},{"key":"558_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.21","volume":"1","author":"X Gerard","year":"2012","unstructured":"Gerard X, Perrault I, Hanein S, Silva E, Bigot K, Defoort-Delhemmes S, et al. AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation. Mol Ther Nucleic Acids. 2012;1: e29. https:\/\/doi.org\/10.1038\/mtna.2012.21.","journal-title":"Mol Ther Nucleic Acids."},{"key":"558_CR59","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.omtn.2018.07.010","volume":"12","author":"K Dulla","year":"2018","unstructured":"Dulla K, Aguila M, Lane A, Jovanovic K, Parfitt DA, Schulkens I, et al. Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c.2991+1655A>G LCA10 models. Mol Ther Nucleic Acids. 2018;12:730\u201340. https:\/\/doi.org\/10.1016\/j.omtn.2018.07.010.","journal-title":"Mol Ther Nucleic Acids."},{"key":"558_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","volume":"25","author":"AV Cideciyan","year":"2019","unstructured":"Cideciyan AV, Jacobson SG, Drack AV, Ho AC, Charng J, Garafalo AV, et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat Med. 2019;25:225\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0295-0.","journal-title":"Nat Med"},{"key":"558_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-75402-4_11","volume":"1074","author":"A Garanto","year":"2018","unstructured":"Garanto A, van der Velde-Visser SD, Cremers FPM, Collin RWJ. Antisense oligonucleotide-based splice correction of a deep-intronic mutation in CHM underlying choroideremia. Adv Exp Med Biol. 2018;1074:83\u20139. https:\/\/doi.org\/10.1007\/978-3-319-75402-4_11.","journal-title":"Adv Exp Med Biol"},{"key":"558_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.89","volume":"5","author":"RW Slijkerman","year":"2016","unstructured":"Slijkerman RW, Vache C, Dona M, Garcia-Garcia G, Claustres M, Hetterschijt L, et al. Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation. Mol Ther Nucleic Acids. 2016;5: e381. https:\/\/doi.org\/10.1038\/mtna.2016.89.","journal-title":"Mol Ther Nucleic Acids."},{"key":"558_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/genes10060452","author":"A Garanto","year":"2019","unstructured":"Garanto A, Duijkers L, Tomkiewicz TZ, Collin RWJ. Antisense oligonucleotide screening to optimize the rescue of the splicing defect caused by the recurrent deep-intronic ABCA4 variant c.4539+2001G>A in Stargardt disease. Genes (Basel). 2019. https:\/\/doi.org\/10.3390\/genes10060452.","journal-title":"Genes (Basel)."},{"key":"558_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/genes10050363","author":"S Naessens","year":"2019","unstructured":"Naessens S, Ruysschaert L, Lefever S, Coppieters F, De Baere E. Antisense oligonucleotide-based downregulation of the G56R pathogenic variant causing NR2E3-associated autosomal dominant retinitis pigmentosa. Genes (Basel). 2019. https:\/\/doi.org\/10.3390\/genes10050363.","journal-title":"Genes (Basel)."},{"key":"558_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2013.183","author":"M Moosajee","year":"2014","unstructured":"Moosajee M, Ramsden SC, Black GC, Seabra MC, Webster AR. Clinical utility gene card for: choroideremia. Eur J Hum Genet. 2014. https:\/\/doi.org\/10.1038\/ejhg.2013.183.","journal-title":"Eur J Hum Genet"},{"key":"558_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.exer.2017.01.001","volume":"155","author":"R Richardson","year":"2017","unstructured":"Richardson R, Smart M, Tracey-White D, Webster AR, Moosajee M. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Exp Eye Res. 2017;155:24\u201337. https:\/\/doi.org\/10.1016\/j.exer.2017.01.001.","journal-title":"Exp Eye Res"},{"key":"558_CR67","first-page":"93","volume":"1","author":"J Davies","year":"1965","unstructured":"Davies J, Gorini L, Davis BD. Misreading of RNA codewords induced by aminoglycoside antibiotics. Mol Pharmacol. 1965;1:93\u2013106.","journal-title":"Mol Pharmacol"},{"key":"558_CR68","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1093\/hmg\/ddn302","volume":"17","author":"M Moosajee","year":"2008","unstructured":"Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY. Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet. 2008;17:3987\u20134000. https:\/\/doi.org\/10.1093\/hmg\/ddn302.","journal-title":"Hum Mol Genet"},{"key":"558_CR69","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","volume":"25","author":"M Moosajee","year":"2016","unstructured":"Moosajee M, Tracey-White D, Smart M, Weetall M, Torriano S, Kalatzis V, et al. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. Hum Mol Genet. 2016;25:3416\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddw184.","journal-title":"Hum Mol Genet"},{"key":"558_CR70","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"558_CR71","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.1038\/s41598-018-26481-7","volume":"8","author":"S Torriano","year":"2018","unstructured":"Torriano S, Erkilic N, Baux D, Cereso N, De Luca V, Meunier I, et al. The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy. Sci Rep. 2018;8:8234. https:\/\/doi.org\/10.1038\/s41598-018-26481-7.","journal-title":"Sci Rep"},{"key":"558_CR72","doi-asserted-by":"publisher","first-page":"14011","DOI":"10.1038\/mtm.2014.11","volume":"1","author":"N Cereso","year":"2014","unstructured":"Cereso N, Pequignot MO, Robert L, Becker F, De Luca V, Nabholz N, et al. Proof of concept for AAV2\/5-mediated gene therapy in iPSc-derived retinal pigment epithelium of choroideremia patients. Mol Ther Methods Clin Dev. 2014;1:14011.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"558_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091068","author":"N Erkilic","year":"2019","unstructured":"Erkilic N, Gatinois V, Torriano S, Bouret P, Sanjurjo-Soriano C, Luca V, et al. A novel chromosomal translocation identified due to complex genetic instability in iPSC generated for choroideremia. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8091068.","journal-title":"Cells"},{"key":"558_CR74","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/10409238.2012.694846","volume":"47","author":"KM Keeling","year":"2012","unstructured":"Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol. 2012;47:444\u201363. https:\/\/doi.org\/10.3109\/10409238.2012.694846.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"558_CR75","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1093\/hmg\/ddz028","volume":"28","author":"H Sarkar","year":"2019","unstructured":"Sarkar H, Mitsios A, Smart M, Skinner J, Welch AA, Kalatzis V, et al. Nonsense-mediated mRNA decay efficiency varies in choroideremia providing a target to boost small molecule therapeutics. Hum Mol Genet. 2019;28:1865\u201371. https:\/\/doi.org\/10.1093\/hmg\/ddz028.","journal-title":"Hum Mol Genet"},{"key":"558_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","volume":"43","author":"I Trapani","year":"2014","unstructured":"Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res. 2014;43:108\u201328. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.08.001.","journal-title":"Prog Retin Eye Res"},{"key":"558_CR77","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00109-013-1006-4","volume":"91","author":"T Tolmachova","year":"2013","unstructured":"Tolmachova T, Tolmachov OE, Barnard AR, de Silva SR, Lipinski DM, Walker NJ, et al. Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo. J Mol Med (Berl). 2013;91:825\u201337. https:\/\/doi.org\/10.1007\/s00109-013-1006-4.","journal-title":"J Mol Med (Berl)"},{"key":"558_CR78","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1089\/104303403322542301","volume":"14","author":"AJ Lotery","year":"2003","unstructured":"Lotery AJ, Yang GS, Mullins RF, Russell SR, Schmidt M, Stone EM, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther. 2003;14:1663\u201371.","journal-title":"Hum Gene Ther"},{"key":"558_CR79","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.1128\/JVI.01327-07","volume":"81","author":"M Allocca","year":"2007","unstructured":"Allocca M, Mussolino C, Garcia-Hoyos M, Sanges D, Iodice C, Petrillo M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol. 2007;81:11372\u201380.","journal-title":"J Virol"},{"key":"558_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jgm.2768","volume":"16","author":"A Black","year":"2014","unstructured":"Black A, Vasireddy V, Chung DC, Maguire AM, Gaddameedi R, Tolmachova T, et al. Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models. J Gene Med. 2014;16:122\u201330. https:\/\/doi.org\/10.1002\/jgm.2768.","journal-title":"J Gene Med"},{"key":"558_CR81","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.scr.2018.01.009","volume":"27","author":"TT Duong","year":"2018","unstructured":"Duong TT, Vasireddy V, Ramachandran P, Herrera PS, Leo L, Merkel C, et al. Use of induced pluripotent stem cell models to probe the pathogenesis of choroideremia and to develop a potential treatment. Stem Cell Res. 2018;27:140\u201350. https:\/\/doi.org\/10.1016\/j.scr.2018.01.009.","journal-title":"Stem Cell Res"},{"key":"558_CR82","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1242\/jcs.180141","volume":"129","author":"M Yamaoka","year":"2016","unstructured":"Yamaoka M, Ando T, Terabayashi T, Okamoto M, Takei M, Nishioka T, et al. PI3K regulates endocytosis after insulin secretion by mediating signaling crosstalk between Arf6 and Rab27a. J Cell Sci. 2016;129:637\u201349. https:\/\/doi.org\/10.1242\/jcs.180141.","journal-title":"J Cell Sci"},{"key":"558_CR83","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1093\/hmg\/ddz130","volume":"28","author":"I Trapani","year":"2019","unstructured":"Trapani I, Auricchio A. Has retinal gene therapy come of age? From bench to bedside and back to bench. Hum Mol Genet. 2019;28:R108\u201318. https:\/\/doi.org\/10.1093\/hmg\/ddz130.","journal-title":"Hum Mol Genet"},{"key":"558_CR84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/ng1097-139","volume":"17","author":"F Marlhens","year":"1997","unstructured":"Marlhens F, Bareil C, Griffoin J-M, Zrenner E, Amalric P, Eliaou C, et al. Mutations in RPE65 cause Leber\u2019s congenital amaurosis. Nat Genet. 1997;17:139\u201341.","journal-title":"Nat Genet"},{"key":"558_CR85","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1073\/pnas.0503460102","volume":"102","author":"G Moiseyev","year":"2005","unstructured":"Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci USA. 2005;102:12413\u20138. https:\/\/doi.org\/10.1073\/pnas.0503460102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"558_CR86","first-page":"92","volume":"28","author":"GM Acland","year":"2001","unstructured":"Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28:92\u20135.","journal-title":"Nat Genet"},{"key":"558_CR87","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ymthe.2005.08.008","volume":"12","author":"GM Acland","year":"2005","unstructured":"Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005;12:1072\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.008.","journal-title":"Mol Ther"},{"key":"558_CR88","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374:1597\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(09)61836-5.","journal-title":"Lancet"},{"key":"558_CR89","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med. 2008;358:2240\u20138.","journal-title":"N Engl J Med"},{"key":"558_CR90","doi-asserted-by":"publisher","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4:120ra15. https:\/\/doi.org\/10.1126\/scitranslmed.3002865.","journal-title":"Sci Transl Med"},{"key":"558_CR91","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(16)30371-3.","journal-title":"Lancet"},{"key":"558_CR92","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8.","journal-title":"Lancet"},{"key":"558_CR93","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet. 2014;383:1129\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(13)62117-0.","journal-title":"Lancet"},{"key":"558_CR94","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMc1509501","volume":"374","author":"TL Edwards","year":"2016","unstructured":"Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med. 2016;374:1996\u20138. https:\/\/doi.org\/10.1056\/NEJMc1509501.","journal-title":"N Engl J Med"},{"key":"558_CR95","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","volume":"24","author":"K Xue","year":"2018","unstructured":"Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP, Patricio MI, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507\u201312. https:\/\/doi.org\/10.1038\/s41591-018-0185-5.","journal-title":"Nat Med"},{"key":"558_CR96","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","volume":"193","author":"IS Dimopoulos","year":"2018","unstructured":"Dimopoulos IS, Hoang SC, Radziwon A, Binczyk NM, Seabra MC, MacLaren RE, et al. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am J Ophthalmol. 2018;193:130\u201342. https:\/\/doi.org\/10.1016\/j.ajo.2018.06.011.","journal-title":"Am J Ophthalmol"},{"key":"558_CR97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","volume":"197","author":"BL Lam","year":"2019","unstructured":"Lam BL, Davis JL, Gregori NZ, MacLaren RE, Girach A, Verriotto JD, et al. Choroideremia gene therapy phase 2 clinical trial: 24-month results. Am J Ophthalmol. 2019;197:65\u201373. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.012.","journal-title":"Am J Ophthalmol"},{"key":"558_CR98","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","volume":"137","author":"MD Fischer","year":"2019","unstructured":"Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial. JAMA Ophthalmol. 2019;137:1247\u201354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3278.","journal-title":"JAMA Ophthalmol."},{"key":"558_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061396","volume":"8","author":"V Vasireddy","year":"2013","unstructured":"Vasireddy V, Mills JA, Gaddameedi R, Basner-Tschakarjan E, Kohnke M, Black AD, et al. AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS ONE. 2013;8: e61396. https:\/\/doi.org\/10.1371\/journal.pone.0061396.","journal-title":"PLoS ONE"},{"key":"558_CR100","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"M Ross","year":"2021","unstructured":"Ross M, Ofri R. The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res. 2021;16:1751\u20139. https:\/\/doi.org\/10.4103\/1673-5374.306063.","journal-title":"Neural Regen Res"},{"key":"558_CR101","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445\u201351. https:\/\/doi.org\/10.1038\/nrg3742.","journal-title":"Nat Rev Genet"},{"key":"558_CR102","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5:189ra76. https:\/\/doi.org\/10.1126\/scitranslmed.3005708.","journal-title":"Sci Transl Med."},{"key":"558_CR103","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/hum.2016.111","volume":"28","author":"PS Ramachandran","year":"2017","unstructured":"Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T, et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther. 2017;28:154\u201367. https:\/\/doi.org\/10.1089\/hum.2016.111.","journal-title":"Hum Gene Ther"},{"key":"558_CR104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135112","author":"LC Byrne","year":"2020","unstructured":"Byrne LC, Day TP, Visel M, Strazzeri JA, Fortuny C, Dalkara D, et al. In vivo-directed evolution of adeno-associated virus in the primate retina. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.135112.","journal-title":"JCI Insight."},{"key":"558_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060218","volume":"8","author":"AR Bruewer","year":"2013","unstructured":"Bruewer AR, Mowat FM, Bartoe JT, Boye SL, Hauswirth WW, Petersen-Jones SM. Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS ONE. 2013;8: e60218. https:\/\/doi.org\/10.1371\/journal.pone.0060218.","journal-title":"PLoS ONE"},{"key":"558_CR106","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","volume":"24","author":"T Bordet","year":"2019","unstructured":"Bordet T, Behar-Cohen F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today. 2019;24:1685\u201393. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.038.","journal-title":"Drug Discov Today"},{"key":"558_CR107","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpb.2014.12.028","volume":"95","author":"J Adijanto","year":"2015","unstructured":"Adijanto J, Naash MI. Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm. 2015;95:353\u201367. https:\/\/doi.org\/10.1016\/j.ejpb.2014.12.028.","journal-title":"Eur J Pharm Biopharm"},{"key":"558_CR108","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2147\/IJN.S157000","volume":"13","author":"RA Kelley","year":"2018","unstructured":"Kelley RA, Conley SM, Makkia R, Watson JN, Han Z, Cooper MJ, et al. DNA nanoparticles are safe and nontoxic in non-human primate eyes. Int J Nanomed. 2018;13:1361\u201379. https:\/\/doi.org\/10.2147\/IJN.S157000.","journal-title":"Int J Nanomed"},{"key":"558_CR109","doi-asserted-by":"publisher","first-page":"E517","DOI":"10.1073\/pnas.1218933110","volume":"110","author":"AV Cideciyan","year":"2013","unstructured":"Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA. 2013;110:E517\u201325. https:\/\/doi.org\/10.1073\/pnas.1218933110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"558_CR110","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/mt.2008.126","volume":"16","author":"C Hippert","year":"2008","unstructured":"Hippert C, Dubois G, Morin C, Disson O, Ibanes S, Jacquet C, et al. Gene transfer may be preventive but not curative for a lysosomal transport disorder. Mol Ther. 2008;16:1372\u201381.","journal-title":"Mol Ther"},{"key":"558_CR111","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/hum.2016.040","volume":"27","author":"L Petit","year":"2016","unstructured":"Petit L, Khanna H, Punzo C. Advances in gene therapy for diseases of the eye. Hum Gene Ther. 2016;27:563\u201379. https:\/\/doi.org\/10.1089\/hum.2016.040.","journal-title":"Hum Gene Ther"},{"key":"558_CR112","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/21678707.2015.1046434","volume":"3","author":"IS Dimopoulos","year":"2015","unstructured":"Dimopoulos IS, Chan S, MacLaren RE, MacDonald IM. Pathogenic mechanisms and the prospect of gene therapy for choroideremia. Expert Opin Orphan Drugs. 2015;3:787\u201398. https:\/\/doi.org\/10.1517\/21678707.2015.1046434.","journal-title":"Expert Opin Orphan Drugs"},{"key":"558_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107834","volume":"189","author":"AA Kondkar","year":"2019","unstructured":"Kondkar AA, Abu-Amero KK. Leber congenital amaurosis: current genetic basis, scope for genetic testing and personalized medicine. Exp Eye Res. 2019;189: 107834. https:\/\/doi.org\/10.1016\/j.exer.2019.107834.","journal-title":"Exp Eye Res"},{"key":"558_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.08.009","author":"KT Jayasundera","year":"2021","unstructured":"Jayasundera KT, Abuzaitoun RO, Lacy GD, Abalem MF, Saltzman GM, Ciulla TA, et al. Challenges of cost-effectiveness analyses of novel therapeutics for inherited retinal diseases: cost-effectiveness analysis in inherited retinal diseases. Am J Ophthalmol. 2021. https:\/\/doi.org\/10.1016\/j.ajo.2021.08.009.","journal-title":"Am J Ophthalmol"},{"key":"558_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100827","volume":"77","author":"AV Garafalo","year":"2020","unstructured":"Garafalo AV, Cideciyan AV, Heon E, Sheplock R, Pearson A, WeiYang YuC, et al. Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives. Prog Retin Eye Res. 2020;77: 100827. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.100827.","journal-title":"Prog Retin Eye Res"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-021-00558-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T21:22:42Z","timestamp":1638048162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-021-00558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s40291-021-00558-y","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"9 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding sources were used to prepare the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A-FR and IM have no conflicts of interest to declare. VK is scientific co-founder and consultant of Horama.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Signed informed consent was obtained from the patients regarding publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"VK performed the literature search and wrote the first draft of the manuscript. VK, A-FR and IM analysed data, prepared figures and critically reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}